[A coherent radiotherapeutic-surgical approach, based on PSA, for the management of cancer of the prostate].
The presence of cancer of the prostate does not mean that a patient will succumb to the disease. In fact, prior to the advent of prostate-specific antigen (PSA) testing, the cause of death in 50% of men with detectable extraglandular cancer was intercurrent disease. No studies have conclusively demonstrated a definitive benefit of surgery or radiation over simple observation; therefore treatment complications must absolutely be restricted to a bare minimum while demonstrating curative effect. This review presents a balanced perspective on the management of prostate cancer which results from non-adversarial, extensive, and continuous interactions between two very active Departments (Urology and Radiation Oncology). Such a multidisciplinary approach fosters relevant research projects and ultimately benefits patient care.
Kagan
A R
AR
Department of Radiation Oncology, Southern California Kaiser Permanente Medical Group, Los Angeles.
Zimmern
P E
PE
Hintz
B
B
Himsl
K K
KK
D000368:Aged; D003131:Combined Modality Therapy; D012739:Gonadal Steroid Hormones / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008991:Monitoring, Physiologic; D009364:Neoplasm Recurrence, Local; D017430:Prostate-Specific Antigen / Q000032:analysis*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000628:therapy
D012739:Gonadal Steroid Hormones; D017430:Prostate-Specific Antigen